首页> 外文期刊>Scandinavian journal of urology >Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours
【24h】

Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours

机译:基于人群的原发性T1期膀胱肿瘤复发和进展的预后因素研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective. Stage T1 urothelial carcinoma of the bladder (UCB) exhibits heterogeneous clinical behaviour, and the treatment is controversial. The aim of this study was to evaluate prognostic factors for UCB in a defined, population-based cohort comprising patients with a first time diagnosis of primary stage T1 UCB. Material and methods. The study population initially consisted of 285 patients with primary stage T1 UCB reported to the regional Bladder Cancer Registry in the Southeast Healthcare Region of Sweden from 1992 to 2001. The histological specimens were re-evaluated concerning stage, substaging of T1, World Health Organization (WHO) grade, lymphovascular invasion (LVI), tumour volume and total resected volume. Hospital records provided data on tumour size and multiplicity, occurrence of possible relapse and/or progression, death from UCB and whether treatment was given. Results. After re-evaluation, the study population comprised 211 patients. The median follow-up time was 60 months. LVI was a prognostic factor for UCB progression and recurrence. Tumour size larger than 30 mm and multiplicity increased the risk of recurrence. T1 substaging, tumour volume and total resected volume were not associated with recurrence or tumour progression. Conclusions. LVI is significantly correlated with progression and recurrence in patients with primary stage T1 UCB. Therefore, the presence of LVI should be evaluated in every new case of T1 UCB.
机译:目的。 T1期膀胱尿路上皮癌(UCB)表现出不同的临床行为,并且治疗方法存在争议。这项研究的目的是评估一个确定的,以人群为基础的队列研究中UCB的预后因素,该人群包括初次诊断为T1期UCB的患者。材料与方法。研究人群最初包括285例1992年至2001年向瑞典东南医疗区膀胱癌登记地区报告的原发性T1期UCB患者。对组织学标本进行了重新评估,涉及阶段,T1的分类,世界卫生组织( WHO)级,淋巴管浸润(LVI),肿瘤体积和总切除体积。医院记录提供了有关肿瘤大小和多样性,可能复发和/或进展的发生,UCB死亡以及是否接受治疗的数据。结果。重新评估后,研究人群包括211名患者。中位随访时间为60个月。 LVI是UCB进展和复发的预后因素。肿瘤大小大于30毫米且多重性增加了复发的风险。 T1亚型,肿瘤体积和总切除体积与复发或肿瘤进展无关。结论。 LVI与原发性T1 UCB患者的进展和复发显着相关。因此,在每个新的T1 UCB病例中都应评估LVI的存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号